Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy
Txylo.com/10294087
Trending...
- Governor Abbott Announces Mexia Designated Music Friendly Texas Certified Community
- Contact Levi & Korsinsky by December 6, 2024 Deadline to Join Class Action Against Iris Energy Limited(IREN)
- Los Defensores Joins ABC13's Share Your Holidays Food Drive to Support Houston Families
~ Houston, USA - The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, has been presented at a major global academic conference, garnering significant attention in the field of immunotherapy.
On November 25, Hanmi announced that it had presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference. The conference was held from November 6 to 10 in Houston, USA.
BH3120 is a novel anticancer drug based on Hanmi's proprietary dual antibody platform, "Pentambody." This technology allows a single antibody to simultaneously bind to two distinct targets, enabling targeted anticancer action by specifically attacking cancer cells while activating immune cells to enhance immunotherapy effects.
The drug is designed to target PD-L1 on cancer cells and 4-1BB on immune cells, acting as a "bridge" that facilitates immune cells' recognition and killing of tumor cells. Unlike other 4-1BB-targeting antibody candidates that have faced challenges with efficacy or safety, BH3120's preclinical studies have shown robust anticancer efficacy and a unique decoupling of immune activity between the tumor microenvironment (TME) and normal tissues. This distinct mechanism highlights BH3120's potential as a breakthrough in developing an effective and safer anticancer therapy.
More on Txylo.com
During the SITC presentation, Hanmi outlined the background, design, and clinical progress of BH3120. Currently, a global Phase 1 clinical trial is underway in South Korea and the United States to assess the safety and tolerability of BH3120 as a monotherapy in patients with advanced or metastatic solid tumors.
The Phase 1 clinical trial has progressed smoothly through cohort 3 (1 mg/kg) of the dose escalation phase with no dose-limiting toxicities (DLT) or grade 3 or higher adverse drug reactions observed to date. Dr. Dong-wan Kim, director of the Seoul National University Hospital Clinical Trials Center (Hemato-Oncology Department) and lead investigator for the phase 1 clinical trial of BH3120, expressed optimism about achieving positive outcomes. He stated, "The phase 1 clinical trial of BH3120 is a critical step in verifying the potential of this next-generation immunotherapy. We are optimistic about achieving positive outcomes." He also added, "We hope further research will establish BH3120 as an effective and safe treatment option for various cancer types, reducing the side effects often associated with current immunotherapies."
In parallel, Hanmi is also conducting a Phase 1 trial to assess the safety and efficacy of BH3120 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced or metastatic solid tumors.
More on Txylo.com
In September, Hanmi obtained approval from both the Korean Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) to modify the Phase 1 trial plan to evaluate BH3120 in combination with KEYTRUDA. Full-scale clinical development is expected to commence early next year. Hanmi will serve as the lead sponsor and conduct the clinical trial while MSD will supply KEYTRUDA for the trial.
Young Su Noh, Director of Hanmi's ONCO Clinical Team, emphasized that this BH3120 trial represents a milestone as Hanmi's first global clinical research project utilizing their proprietary Pentambody dual antibody platform in immuno-oncology - a field at the forefront of cancer treatment innovation. He stated, "We are committed to advancing a next-generation immunotherapy that overcomes the limitations of existing treatments and enhances therapeutic efficacy."
For more information on BH3120 and Hanmi Pharmaceutical, please visit their official websites at www.hanmipharm.com or contact them at +08-2-410-0467. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
On November 25, Hanmi announced that it had presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference. The conference was held from November 6 to 10 in Houston, USA.
BH3120 is a novel anticancer drug based on Hanmi's proprietary dual antibody platform, "Pentambody." This technology allows a single antibody to simultaneously bind to two distinct targets, enabling targeted anticancer action by specifically attacking cancer cells while activating immune cells to enhance immunotherapy effects.
The drug is designed to target PD-L1 on cancer cells and 4-1BB on immune cells, acting as a "bridge" that facilitates immune cells' recognition and killing of tumor cells. Unlike other 4-1BB-targeting antibody candidates that have faced challenges with efficacy or safety, BH3120's preclinical studies have shown robust anticancer efficacy and a unique decoupling of immune activity between the tumor microenvironment (TME) and normal tissues. This distinct mechanism highlights BH3120's potential as a breakthrough in developing an effective and safer anticancer therapy.
More on Txylo.com
- Texas: Governor Abbott Appoints Fletcher To Board Of Pardons And Paroles
- NEW RELEASE: Dark Woods Rising by A J Dalton
- Burrows Cabinets Launches Slim Shaker Doors in 19 Color Options
- Crunch Fitness Franchise Unveils Its First 3.0 Gym Design with the Opening of Crunch East Plano
- Youth Group Makes History as First Visitors to National Electronics Museum
During the SITC presentation, Hanmi outlined the background, design, and clinical progress of BH3120. Currently, a global Phase 1 clinical trial is underway in South Korea and the United States to assess the safety and tolerability of BH3120 as a monotherapy in patients with advanced or metastatic solid tumors.
The Phase 1 clinical trial has progressed smoothly through cohort 3 (1 mg/kg) of the dose escalation phase with no dose-limiting toxicities (DLT) or grade 3 or higher adverse drug reactions observed to date. Dr. Dong-wan Kim, director of the Seoul National University Hospital Clinical Trials Center (Hemato-Oncology Department) and lead investigator for the phase 1 clinical trial of BH3120, expressed optimism about achieving positive outcomes. He stated, "The phase 1 clinical trial of BH3120 is a critical step in verifying the potential of this next-generation immunotherapy. We are optimistic about achieving positive outcomes." He also added, "We hope further research will establish BH3120 as an effective and safe treatment option for various cancer types, reducing the side effects often associated with current immunotherapies."
In parallel, Hanmi is also conducting a Phase 1 trial to assess the safety and efficacy of BH3120 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced or metastatic solid tumors.
More on Txylo.com
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
- Communities In Schools of the Heart of Texas Announces New CEO
- Shape the Future of OpenSSL: Election Period Open Now!
- LIB Empowers Uzbekistan's Automotive Industry: A New Era of Quality Assurance
- TijaraIQ.com Launches as Iraq's Free Marketplace for Buying, Selling, and Creating Opportunities
In September, Hanmi obtained approval from both the Korean Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) to modify the Phase 1 trial plan to evaluate BH3120 in combination with KEYTRUDA. Full-scale clinical development is expected to commence early next year. Hanmi will serve as the lead sponsor and conduct the clinical trial while MSD will supply KEYTRUDA for the trial.
Young Su Noh, Director of Hanmi's ONCO Clinical Team, emphasized that this BH3120 trial represents a milestone as Hanmi's first global clinical research project utilizing their proprietary Pentambody dual antibody platform in immuno-oncology - a field at the forefront of cancer treatment innovation. He stated, "We are committed to advancing a next-generation immunotherapy that overcomes the limitations of existing treatments and enhances therapeutic efficacy."
For more information on BH3120 and Hanmi Pharmaceutical, please visit their official websites at www.hanmipharm.com or contact them at +08-2-410-0467. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Dr. Sathish Palayam Speaks at the Full Arch Growth Conference, Sharing Insights to Revolutionize Patient Care!
- Louisiana Gastroenterology Associates Becomes Preferred Employer Partner For Remington College
- Donors and Recipients of Nashville Chopin's Metro School Piano Donation Program Announced
- Network for Good / Bonterra's Abhorrent Behavior Leaves Nonprofits in the Lurch
- Iris Energy Limited Sued for Securities Law Violations - Contact The Gross Law Firm Before December 6, 2024 to Discuss Your Rights - IREN
- Loyal American Airlines Passenger and Son of 33-Year Employee Files Legal Action Against Airline for Racial Bias, Unlawful Ban, and Injustice
- Texas: Governor Abbott Appoints Patel To Correctional Managed Health Care Committee
- Governor Abbott Announces Over $15 Million In Career Training Grants Across Texas
- Fathom Holdings Expands Verus Title Elite into Amarillo, Texas
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Texas: Governor Abbott Launches Small Business Freedom Council
- Britive's Continued Innovation Meets Growing Demands for PAM Equipped for Multi-Cloud Enterprise Environments
- Pittsburgh Professional Women invites all Women and Allies to MONEY CLUB
- Speranza Dental Implant Center's New Website Launch!
- Education Through Music-Los Angeles to Host 19th Year Benefit Gala on Friday December 6th at Skirball Cultural Center
- Celebrating A Decade Of Young Storytellers: The 10th Annual Flint Youth Film Festival Opens For Entries
- Mobility Infotech: A Leader in Custom Software Development Services in 2024
- United Heritage Credit Union Donates $20,000 to BookSpring
- Tween Magazine Launches to Empower and Inspire Preteen Girls
- ABBYY Positioned as the Leader in the 2024 SPARK Matrix™ for Intelligent Document Processing (IDP) by QKS Group